A 52-year-old woman is evaluated in the emergency department for a fever of 38.8°C (101.8°F) and severe chills that began 2 hours ago. She was diagnosed with acute myeloid leukemia 3 weeks ago and is currently undergoing induction chemotherapy. She has an indwelling central venous catheter. Her blood pressure is 105/65 mm Hg, pulse is 110/min, and respirations are 18/min. Physical examination reveals a well-healed catheter site with no erythema or purulent drainage, and the remainder of the examination shows no obvious source of infection. A complete blood count reveals an absolute neutrophil count of 150/mm³. Arrange the following management steps in the most appropriate chronological order for this patient.
- 1Obtain blood cultures from the central venous catheter and a peripheral vein
- 2Administer empiric intravenous cefepime or piperacillin-tazobactam
- 3Reassess clinical status and modify antibiotics based on culture results at 48 to 72 hours
- 4Add empiric antifungal therapy if the patient remains febrile after 4 to 7 days of treatment
Cevap
The correct sequence for managing high-risk febrile neutropenia is to first obtain blood cultures from central and peripheral sites, immediately follow with broad-spectrum antipseudomonal antibacterial therapy, reassess the patient at 48-72 hours when preliminary culture results return, and finally add empiric antifungal coverage if the fever persists beyond 4-7 days.
Febrile neutropenia is an oncologic and infectious disease emergency defined by an absolute neutrophil count (ANC) < 500/mm³ and a single oral temperature of ≥ 38.3°C (101.0°F) or ≥ 38.0°C (100.4°F) sustained over 1 hour. Because these patients lack the primary cellular defense against bacterial invasion, infections can rapidly disseminate and cause fatal septic shock. The universally accepted management algorithm dictates a strict chronological sequence. First, appropriate diagnostic tests must be secured: at least two sets of blood cultures (including one from any indwelling central venous catheter and one from a peripheral vein) should be drawn. Second, immediately after drawing cultures—and ideally within 60 minutes of presentation—empiric intravenous broad-spectrum antibacterial therapy with antipseudomonal activity (e.g., cefepime, meropenem, or piperacillin-tazobactam) must be initiated. Third, the patient is closely monitored and reassessed at 48 to 72 hours; this milestone is crucial because initial blood culture results will return, permitting the de-escalation or modification of antibiotics based on susceptibilities. Fourth, if the patient remains persistently febrile and profoundly neutropenic after 4 to 7 days of appropriate broad-spectrum antibacterial therapy, an occult invasive fungal infection (such as Candida or Aspergillus) is presumed, and empiric antifungal therapy (e.g., an echinocandin or a mold-active azole) is added to the regimen.
Adım Adım Çözüm
Anahtar Kavram
Management algorithm for febrile neutropenia